Dr. Christopher James Anker, MD

Dr. Anker practices at University of Vermont Medical Center in Burlington, Vermont, part of University of Vermont Health Network.

Dr. Anker's NPI, 1053507434, was assigned on September 19, 2007. Dr. Anker graduated from State University of NY Upstate Medical University in 2005. Dr. Anker holds Vermont license 042.0012785.

Dr. Anker's primary practice is University of Vermont Medical Center, at 111 Colchester Ave, Burlington, VT 05401 in Chittenden County. The practice phone is (802) 847-0000.

Dr. Anker's primary practice is University of Vermont Medical Center in Burlington, Vermont, part of University of Vermont Health Network. Dr. Anker is also affiliated with Central Vermont Medical Center. The medical group on file is University of Vermont Medical Center. Dmand AI also links Dr. Anker to 1 more hospital and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Anker practices, 4 sites in all. Vendor and product names are available with a free account.

Therapeutic radiology is Dr. Anker's primary specialty in the NPI Registry, under taxonomy code 2085R0203X. Dmand AI has Dr. Anker's licenses on file in 2 states: Vermont and Utah.

CMS data shows 1,067 Medicare services from Dr. Anker across 14 procedure codes in 2024, for 205 Medicare patients. Medicare paid $76,853 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 205 Medicare patients who saw Dr. Anker in 2024. The largest group is 75 to 84, with 86 patients. 68% of them have high blood pressure, and 63% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Anker's median patient age at 73, with 46% women.

In 2024, Dr. Anker wrote 122 Medicare Part D claims for 48 patients. 93% of them were for generic drugs. CMS names the drug for 50 of them, across 3 drugs with 11 or more claims each, at $521 in total drug cost. In 2023, CMS named 72 claims across 6 drugs.

Dr. Anker accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Anker as offering telehealth.

Dmand AI links 59 papers to Dr. Anker, published from 2010 to 2025. 2022 was the busiest year, with 6. The most frequent topics are Chemoradiotherapy, Adenocarcinoma and Lung Neoplasms. Dr. Anker has published most often in Int J Radiat Oncol Biol Phys. Dr. Anker's most frequent co-authors are Suzanne M. Russo, MD, Percy Po-Yih Lee, MD and Nataniel Hernan Lester-Coll, MD.

Dmand AI links Dr. Anker to 8 clinical trials, 5 of them phase 3 studies. 6 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Carcinoma, Hepatocellular. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 2 general payments to Dr. Anker from 2 drug and device companies from 2018 to 2020. Food and beverage make up the largest share, 88% of the total. Novartis Pharmaceuticals Corporation paid the most, $113.

Dr. Anker graduated from State University of NY Upstate Medical University in 2005.